Literature DB >> 28258698

Introduction to checkpoint inhibitors and cancer immunotherapy.

Arlene H Sharpe1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28258698      PMCID: PMC5362112          DOI: 10.1111/imr.12531

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


× No keyword cloud information.
  27 in total

Review 1.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

Review 2.  Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma.

Authors:  Liliana E Lucca; David A Hafler
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

Review 3.  Immunoregulatory functions of VISTA.

Authors:  Elizabeth C Nowak; J Louise Lines; Frederick S Varn; Jie Deng; Aurelien Sarde; Rodwell Mabaera; Anna Kuta; Isabelle Le Mercier; Chao Cheng; Randolph J Noelle
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

Review 4.  Viewing Siglecs through the lens of tumor immunology.

Authors:  Isabella Fraschilla; Shiv Pillai
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

Review 5.  The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.

Authors:  Murali Janakiram; Urvi A Shah; Weifeng Liu; Aimin Zhao; Mark P Schoenberg; Xingxing Zang
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

Review 6.  TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy.

Authors:  Yemsratch T Akalu; Carla V Rothlin; Sourav Ghosh
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

7.  Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.

Authors:  David F McDermott; Charles G Drake; Mario Sznol; Toni K Choueiri; John D Powderly; David C Smith; Julie R Brahmer; Richard D Carvajal; Hans J Hammers; Igor Puzanov; F Stephen Hodi; Harriet M Kluger; Suzanne L Topalian; Drew M Pardoll; Jon M Wigginton; Georgia D Kollia; Ashok Gupta; Dan McDonald; Vindira Sankar; Jeffrey A Sosman; Michael B Atkins
Journal:  J Clin Oncol       Date:  2015-03-30       Impact factor: 44.544

8.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

9.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

10.  Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.

Authors:  P Waterhouse; J M Penninger; E Timms; A Wakeham; A Shahinian; K P Lee; C B Thompson; H Griesser; T W Mak
Journal:  Science       Date:  1995-11-10       Impact factor: 47.728

View more
  47 in total

1.  RNA Interference-Based Cancer Drugs: The Roadblocks, and the "Delivery" of the Promise.

Authors:  Manisit Das; Sara Musetti; Leaf Huang
Journal:  Nucleic Acid Ther       Date:  2018-12-18       Impact factor: 5.486

2.  Targeting macrophage checkpoint inhibitor SIRPα for anticancer therapy.

Authors:  Jie Liu; Seethu Xavy; Shirley Mihardja; Sharline Chen; Kavitha Sompalli; Dongdong Feng; Timothy Choi; Balaji Agoram; Ravindra Majeti; Irving L Weissman; Jens-Peter Volkmer
Journal:  JCI Insight       Date:  2020-06-18

Review 3.  A novel role for coinhibitory receptors/checkpoint proteins in the immunopathology of sepsis.

Authors:  Eleanor A Fallon; Bethany M Biron-Girard; Chun-Shiang Chung; Joanne Lomas-Neira; Daithi S Heffernan; Sean F Monaghan; Alfred Ayala
Journal:  J Leukoc Biol       Date:  2018-02-02       Impact factor: 4.962

Review 4.  Cancer stem cells: Regulation programs, immunological properties and immunotherapy.

Authors:  Dingxiao Zhang; Dean G Tang; Kiera Rycaj
Journal:  Semin Cancer Biol       Date:  2018-05-09       Impact factor: 15.707

5.  CCR4 Antagonists Inhibit Treg Trafficking into the Tumor Microenvironment.

Authors:  John M Ketcham; Lisa A Marshall; Oezcan Talay
Journal:  ACS Med Chem Lett       Date:  2018-09-10       Impact factor: 4.345

6.  Unique Photochemo-Immuno-Nanoplatform against Orthotopic Xenograft Oral Cancer and Metastatic Syngeneic Breast Cancer.

Authors:  Lu Zhang; Di Jing; Lei Wang; Yuan Sun; Jian Jian Li; Brianna Hill; Fan Yang; Yuanpei Li; Kit S Lam
Journal:  Nano Lett       Date:  2018-10-26       Impact factor: 11.189

Review 7.  T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword.

Authors:  Karin H Simons; Alwin de Jong; J Wouter Jukema; Margreet R de Vries; Ramon Arens; Paul H A Quax
Journal:  Nat Rev Cardiol       Date:  2019-06       Impact factor: 32.419

8.  Discovery of Diaminopyrimidine Carboxamide HPK1 Inhibitors as Preclinical Immunotherapy Tool Compounds.

Authors:  Brandon A Vara; Samuel M Levi; Abdelghani Achab; David A Candito; Xavier Fradera; Charles A Lesburg; Shuhei Kawamura; Brian M Lacey; Jongwon Lim; Joey L Methot; Zangwei Xu; Haiyan Xu; Dustin M Smith; Jennifer A Piesvaux; J Richard Miller; Mark Bittinger; Sheila H Ranganath; David J Bennett; Erin F DiMauro; Alexander Pasternak
Journal:  ACS Med Chem Lett       Date:  2021-03-19       Impact factor: 4.345

9.  Immunotherapy and next-generation sequencing guided therapy for precision oncology: What have we learnt and what does the future hold?

Authors:  Roman Groisberg; Vivek Subbiah
Journal:  Expert Rev Precis Med Drug Dev       Date:  2018-06-18

10.  N-Carboxyanhydride Polymerization of Glycopolypeptides That Activate Antigen-Presenting Cells through Dectin-1 and Dectin-2.

Authors:  Matthew N Zhou; Corleone S Delaveris; Jessica R Kramer; Justin A Kenkel; Edgar G Engleman; Carolyn R Bertozzi
Journal:  Angew Chem Int Ed Engl       Date:  2018-02-21       Impact factor: 15.336

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.